Kala Pharmaceuticals (KALA) PT Raised to $22 at Oppenheimer, After Receiving FDA Approval
Tweet
Share
E-mailGet Alerts KALA Hot Sheet
Price: $0.92 +4.55%
Rating Summary:
5 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
5 Buy, 5 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Oppenheimer analyst Francois Brisebois raised the price target on Kala Pharmaceuticals (NASDAQ: KALA) to $22.00 (from $21.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
- Macquarie Upgrades Inventec Corp (2356:TT) to Neutral
- STAAR Surgical (STAA) PT Lowered to $28 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
